PDF herunterladen
Thromb Haemost 2012; 108(06): 1180-1191
DOI: 10.1160/TH12-05-0310
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor

Mark Y. Chan
1   National University Heart Centre, Singapore
,
Min Lin
2   Duke Translational Medicine Institute, Durham, North Carolina, USA
,
Joseph Lucas
3   Center for Applied Genomics and Technology, Duke Institute for Genome Sciences &Policy, Durham, North Carolina, USA
,
Arthur Moseley
4   Proteomics Core Facility, Duke Institute for Genome Sciences &Policy, Durham, North Carolina, USA
,
J Will Thompson
4   Proteomics Core Facility, Duke Institute for Genome Sciences &Policy, Durham, North Carolina, USA
,
Derek Cyr
3   Center for Applied Genomics and Technology, Duke Institute for Genome Sciences &Policy, Durham, North Carolina, USA
,
Hitoshi Ueda
5   Bayer Yakuhin Ltd, Osaka, Japan
,
Mariko Kajikawa
5   Bayer Yakuhin Ltd, Osaka, Japan
,
Thomas L. Ortel
6   Duke University Medical Center Hemostasis &Thrombosis Center Core Laboratory, Durham, North Carolina, USA
,
Richard C. Becker
6   Duke University Medical Center Hemostasis &Thrombosis Center Core Laboratory, Durham, North Carolina, USA
7   Duke Clinical Research Institute, Durham, North Carolina, USA
› Institutsangaben Financial support:This study was funded by Bayer Yakuhin Ltd, Osaka, Japan. Bayer Yakuhin had no direct role in the laboratorial and statistical analysis, data interpretation or drafting of the manuscript. Dr. Mark Y. Chan receives salary support from the National Medical Research Council as a recipient of the Singapore Clinician-Scientist Award (NMRC/ CSA/028/2010).
Weitere Informationen

Publikationsverlauf

Received: 13. Mai 2012

Accepted after major revision: 11. September 2012

Publikationsdatum:
30. November 2017 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Summary

Plasma proteins mediate thrombogenesis, inflammation, endocardial injury and structural remodelling in atrial fibrillation (AF). We hypothesised that anti-coagulation with rivaroxaban, a direct factor Xa inhibitor, would differentially modulate biologically-relevant plasma proteins, compared with warfarin, a multi-coagulation protein antagonist. We performed unbiased liquid chromatography/tandem mass spectroscopy and candidate multiplexed protein immunoassays among Japanese subjects with non-valvular chronic AF who were randomly assigned to treatment with 24 weeks of rivaroxaban (n=93) or warfarin (n=94). Nine metaproteins, including fibulin-1 (p=0.0033), vitronectin (p=0.0010), haemoglobin α(p=0.0012), apolipoproteins C-II (p=0.0017) and H (p=0.0023), complement C5 precursor (p=0.0026), coagulation factor XIIIA (p=0.0026) and XIIIB (p=0.0032) subunits, and 10 candidate proteins, including thrombomodulin (p=0.0004), intercellular adhesion molecule-3 (p=0.0064), interleukin-8 (p=0.0007) and matrix metalloproteinase-3 (p=0.0003), were differentially expressed among patients with and without known clinical risk factors for stroke and bleeding in AF. Compared with warfarin, rivaroxaban treatment was associated with a greater increase in thrombomodulin (Δ0.1 vs. 0.3 pg/ml, p=0.0026) and a trend towards a reduction in matrix metalloproteinase-9 (Δ2.2 vs. –4.9 pg/ml, p=0.0757) over 24 weeks. Only modest correlations were observed between protein levels and prothrombin time, factor Xa activity and prothrombinase-induced clotting time. Plasma proteomics can identify distinct functional patterns of protein expression that report on known stroke and bleeding risk phenotypes in an ethnically-homogeneous AF population. The greater upregulation of thrombomodulin among patients randomised to rivaroxaban represents a proof-of-principle that pharmacoproteomics can be employed to discern novel effects of factor Xa inhibition beyond standard pharmacodynamic measures.

Keywords

Atrial fibrillation - Proteomics - Thrombomodulin - warfarin and factor Xa inhibitor

 

  • References

  • 1 Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet 2009; 373: 155-166.
    CrossrefPubMedGoogle Scholar
  • 2 Hertervig EJ, Yuan S, Carlson J. et al. Evidence for electrical remodelling of the atrial myocardium in patients with atrial fibrillation. A study using the monophasic action potential recording technique. Clin Physiol Funct Imaging 2002; 22: 8-12.
    CrossrefPubMedGoogle Scholar
  • 3 Polyakova V, Miyagawa S, Szalay Z. et al. Atrial extracellular matrix remodelling in patients with atrial fibrillation. J Cell Mol Med 2008; 12: 189-208.
    PubMedGoogle Scholar
  • 4 Mayr M, Yusuf S, Weir G. et al. Combined metabolomic and proteomic analysis of human atrial fibrillation. J Am Coll Cardiol 2008; 51: 585-594.
    CrossrefPubMedGoogle Scholar
  • 5 Tchabo NE, Liel MS, Kohn EC. Applying proteomics in clinical trials: assessing the potential and practical limitations in ovarian cancer. Am J Pharmacogenomics 2005; 5: 141-148.
    CrossrefPubMedGoogle Scholar
  • 6 Kirchhof P, Auricchio A, Bax J. et al. Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace 2007; 9: 1006-1023.
    CrossrefPubMedGoogle Scholar
  • 7 Kamath S, Blann AD, Chin BS. et al. A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. J Am Coll Cardiol 2002; 40: 484-490.
    CrossrefPubMedGoogle Scholar
  • 8 Li-Saw-Hee FL, Blann AD, Lip GY. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke 2000; 31: 828-833.
    CrossrefPubMedGoogle Scholar
  • 9 Lucas JE, Kung HN, Chi JT. Latent factor analysis to discover pathway-associated putative segmental aneuploidies in human cancers. PLoS Comput Biol 2010; 6: e1000920.
    CrossrefPubMedGoogle Scholar
  • 10 Lip GY. Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation. Am J Med 2011; 124: 111-114.
    CrossrefPubMedGoogle Scholar
  • 11 Loscalzo J. Personalized cardiovascular medicine and drug development: time for a new paradigm. Circulation 2012; 125: 638-645.
    CrossrefPubMedGoogle Scholar
  • 12 Tu C, Rudnick PA, Martinez MY. et al. Depletion of abundant plasma proteins and limitations of plasma proteomics. J Proteome Res 2010; 9: 4982-4991.
    CrossrefPubMedGoogle Scholar
  • 13 Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol 2005; 563: 23-60.
    CrossrefPubMedGoogle Scholar
  • 14 Ohlin AK, Larsson K, Hansson M. Soluble thrombomodulin activity and soluble thrombomodulin antigen in plasma. J Thromb Haemost 2005; 3: 976-982.
    CrossrefPubMedGoogle Scholar
  • 15 Ito T, Maruyama I. Thrombomodulin: Protectorate God of the vasculature in thrombosis and inflammation. J Thromb Haemost 2011; 9 (Suppl. 01) 168-173
    CrossrefPubMedGoogle Scholar
  • 16 Lind M, Boman K, Johansson L. et al. Thrombomodulin as a marker for bleeding complications during warfarin treatment. Arch Intern Med 2009; 169: 1210-1215.
    CrossrefPubMedGoogle Scholar
  • 17 Yamashita T, Sekiguchi A, Iwasaki YK. et al. Thrombomodulin and tissue factor pathway inhibitor in endocardium of rapidly paced rat atria. Circulation 2003; 108: 2450-2452.
    CrossrefPubMedGoogle Scholar
  • 18 Freestone B, Chong AY, Nuttall S. et al. Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation. Chest 2007; 132: 1253-1258.
    CrossrefPubMedGoogle Scholar
  • 19 Li-Saw-Hee FL, Blann AD, Goldsmith I. et al. Indexes of hypercoagulability measured in peripheral blood reflect levels in intracardiac blood in patients with atrial fibrillation secondary to mitral stenosis. Am J Cardiol 1999; 83: 1206-1209.
    CrossrefPubMedGoogle Scholar
  • 20 Raife TJ, Dwyre DM, Stevens JW. et al. Human thrombomodulin knock-in mice reveal differential effects of human thrombomodulin on thrombosis and atherosclerosis. Arterioscler Thromb Vasc Biol 2011; 31: 2509-2517.
    CrossrefPubMedGoogle Scholar
  • 21 Constans J, Conri C. Circulating markers of endothelial function in cardiovascular disease. Clin Chim Acta 2006; 368: 33-47.
    CrossrefPubMedGoogle Scholar
  • 22 Gramley F, Lorenzen J, Plisiene J. et al. Decreased plasminogen activator inhibitor and tissue metalloproteinase inhibitor expression may promote increased metalloproteinase activity with increasing duration of human atrial fibrillation. J Cardiovasc Electrophysiol 2007; 18: 1076-1082.
    CrossrefPubMedGoogle Scholar
  • 23 Brundel BJ, Shiroshita-Takeshita A, Qi X. et al. Induction of heat shock response protects the heart against atrial fibrillation. Circ Res 2006; 99: 1394-1402.
    CrossrefPubMedGoogle Scholar